arrow
C

Clark C. Chen

brown university health
H指数:40
被引数:5,359

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SADA-17 SURVIVAL AND LOCAL CONTROL AFTER RESECTION AND GAMMATILE BRACHYTHERAPY FOR NEWLY DIAGNOSED BRAIN METASTASES: A PROSPECTIVE REGISTRY ANALYSIS

SADA-17 新诊断脑转移瘤切除联合伽马瓦片近距离放疗后的生存率与局部控制:一项前瞻性登记分析

2026-08-070
OA
Tumor antigen only (TAO) vaccine platforms for glioblastoma therapeutics: a systematic review of evidence from clinical trials

仅肿瘤抗原(TAO)疫苗平台用于胶质母细胞瘤治疗:临床试验证据的系统评价

2026-02-260
OAAI
Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance

前馈miR-181d降解调控甲基鸟嘌呤甲基转移酶群体方差及替莫唑胺耐药性

2025-11-100
OAAI
Variance in Methyl-guanine methyl transferase (MGMT) expression as a defining feature of intra-tumoral heterogeneity that contribute to acquired temozolomide resistance in glioblastoma

MGMT(甲基鸟嘌呤甲基转移酶)表达变异作为肿瘤内异质性的界定特征,其对胶质母细胞瘤获得性替莫唑胺耐药性的贡献。

2025-11-010
OAAI
An atlas of ex vivo drug sensitivity profiles in 666 clinical glioblastoma samples revealed distinct survival-associated networks

一项包含666例临床胶质母细胞瘤样本的离体药物敏感性谱系图谱揭示了与生存相关的独特网络。

2025-11-010
PRE
miR-181d as a master-regulatory microRNA in glioblastomas that regulates RAD51 and MGMT expression to mediate acquired temozolomide resistance and cross-resistance to ionizing radiation

miR-181d作为胶质母细胞瘤中的主调控microRNA,通过调控RAD51和MGMT的表达来介导获得性替莫唑胺耐药以及对电离辐射的交叉耐药。

2025-11-010
OAAI
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

作者更正: 溶瘤DNX-2401病毒疗法联合pembrolizumab治疗复发性胶质母细胞瘤: 1/2期试验

2025-07-210
OA
Droplet Hi-C enables scalable, single-cell profiling of chromatin architecture in heterogeneous tissues (Oct, 10.1038/s41587-024-02447-1, 2024)

Droplet Hi-C技术能够实现对异质性组织中染色质结构的规模化单细胞分析(Oct, 10.1038/s41587-024-02447-1, 2024)

2025-05-120
OA